More patients receiving omeprazole had complete symptom resolution at wk 4 ( 33 % ) and at the end of the study ( 64 % ; both p < 0.001 ) than patients receiving ranitidine ( 8 % and 28 % , respectively ) or ranitidine/metoclopramide ( 7 % and 29 % , respectively ) .
